Hyphens Pharma: Is this pharma company undervalued?

Deejay78 OP : Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. The company’s Specialty Pharma Principals segment sells and markets specialty pharmaceutical products, including Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup, Lidose, and Piascledine through distributorship or licensing, and supply agreements. This segment offers products in various therapeutic areas or medical specialties, including dermatology, pediatrics and neonatology, allergy, otorhinolaryngology consist of ear, nose, and throat, orthopedic and rheumatology, radiology, cardiology and interventional cardiology, ophthalmology, gastroenterology, child psychiatry, and family medicine. Its Proprietary Brands segment develops, markets, and sells its own proprietary range of dermatological products and health supplement products. It offers dermocosmetic products under the Ceradan and TDF brands through medical professionals, including general practitioners, dermatologists, pediatricians, and pharmacists; and health supplement products under the Ocean Health brand directly to consumers via retail channels. The company’s Medical Hypermart and Digital segment engages in the wholesale of pharmaceuticals and medical supplies for healthcare professionals and institutions, and retail pharmacies through tele-sales and sales representatives. This segment also operates an online B2B platform. It also markets and distributes its products in Hong Kong, Myanmar, Brunei, Bangladesh, Cambodia, and Oman. The company was formerly known as Hyphens Pharma International Pte Ltd and changed its name to Hyphens Pharma International Limited in May 2018. Hyphens Pharma International Limited was founded in 1998 and is headquartered in Singapore. Hyphens Pharma International Limited is a subsidiary of Inomed Holding Pte Ltd.

Deejay78 OP : STAY ABOVE 1W MID-BOLINGER BAND (0.323) AND ABOVE MA20 TO TOWARD ADVANCE